NHS Framework for the North of England, Branded Medicine
HS Framework for the North of England, Branded Medicines – Tranche B, Annual Tranche and Insulin Aspart Biosimilar (Trurapi®)
Buyer
The NHS Commissioning Board (operating under the name of NHS England)
Value
£863,999,552
Published
1 Mar 2022
Closes
20 Oct 2021
Procurement details
Source
Find a Tender
Region
United Kingdom
Procurement method
Open
Category
Goods
Contract starts
Not provided
Contract ends
Not provided
CPV classifications
33600000
Pharmaceutical products
Lots
Lot 1 CM/PHR/20/5600/01 - NHS Framework for the NOFE, Branded Medicines - Tranche B
£1
CM/PHR/20/5600/01 - NHS Framework for the North of England, Branded Medicines -Tranche B - 1 March 2022 to 29 February 2024 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months
Delivery: United Kingdom
Lot 2 CM/PHR/20/5600/02 - NHS Framework for the NOFE, Branded Medicines-Annual Tranche
£1
CM/PHR/20/5600/02 - NHS Framework for the North of England, Branded Medicines - Annual Tranche Products. Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months.
Delivery: United Kingdom
Lot 3 CM/PHR/20/5600/03- NHS Framework for Insulin Aspart Biosimilar (Trurapi®)-SofE
£1
CM/PHR/20/5600/03- NHS Framework for Insulin Aspart Biosimilar (Trurapi®), South of England - Period of framework: 1 March 2022 to 31 August 2022 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 6 months.
Delivery: United Kingdom
Lot 4 CM/PHR/20/5600/04-NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London
£1
CM/PHR/20/5600/04 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London - Period of framework: 1 March 2022 to 31 August 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 18 months.
Delivery: United Kingdom
Lot 5 CM/PHR/20/5600/05 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), MaE
£1
CM/PHR/20/5600/05 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), Midlands and East - Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months.
Delivery: United Kingdom
Documents
No document metadata is available for this public record.
Contains public sector information licensed under the Open Government Licence v3.0.